What this pack is
KLOR-CON is the brand name in this record; potassium chloride extended-release tablets is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
KLOR-CONGeneric namepotassium chloride extended-release tablets
How this medicine works
Potassium is a principal intracellular cation involved in nerve transmission, cardiac and skeletal-muscle contraction and renal function. KLOR-CON uses a wax matrix to slow local release; potassium is absorbed before leaving the small intestine while the matrix itself is not absorbed. This mechanism explains why potassium, kidney function and co-medications matter, but cannot decide whether an individual needs supplementation or how many tablets to take.
Read source: United States ↗Current regulatory record · reviewed 2026-08-29More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- KLOR-CON
- Source-scoped market brand names
- KLOR-CON · United StatesCurrent regulator record ↗NDA 019123; both 8 mEq and 10 mEq are prescription RLD products, with 10 mEq also listed as RS; the current label has two exact 100-tablet bottle panels.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- potassium chloride extended-release tablets
- Dosage-form class
- Potassium chloride wax-matrix film-coated extended-release oral tablets: 8 mEq (600 mg potassium chloride) or 10 mEq (750 mg potassium chloride) per tablet; swallow whole without crushing, chewing or sucking; not a KLOR-CON M microencapsulated extended-release tablet
- Route
- Oral (higher-risk electrolyte exact-product identity field)
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
2 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed NDA brand label (SPL v6; published 16 Jul 2025; prescribing information revised Oct 2018)
Potassium chloride 600 mg, equivalent to potassium 8 mEq per tablet; 100-tablet bottle
- Product code
- NDC 0245-5315-11
- Form and route
- KLOR-CON potassium chloride film-coated extended-release oral tablet · oral (intact extended-release tablet product-identity field)
- Container
- 100-tablet prescription bottle label panel
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-29; actual marketing, stock and availability are not established.
- potassium chloride
- 600 mgpotassium chloride mass per tablet; not an individual's tablet count, frequency, course or make-up instruction
- potassium (electrolyte equivalent supplied by potassium chloride)
- 8 mEqmilliequivalents of potassium per tablet; mEq and mg are not one unit that can be converted without the named substance
- Package
- 100 tablets per bottle
- Labelled appearance
- light blue · round, unscored film-coated extended-release tablet, approximately 11 mm · imprint KC / 8Unscored; the cited label says to swallow it whole
United States label · Current U.S. DailyMed NDA brand label (SPL v6; published 16 Jul 2025; prescribing information revised Oct 2018)
Potassium chloride 750 mg, equivalent to potassium 10 mEq per tablet; 100-tablet bottle
- Product code
- NDC 0245-5316-11
- Form and route
- KLOR-CON potassium chloride film-coated extended-release oral tablet · oral (intact extended-release tablet product-identity field)
- Container
- 100-tablet prescription bottle label panel
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-29; actual marketing, stock and availability are not established.
- potassium chloride
- 750 mgpotassium chloride mass per tablet; not an individual's tablet count, frequency, course or make-up instruction
- potassium (electrolyte equivalent supplied by potassium chloride)
- 10 mEqmilliequivalents of potassium per tablet; mEq and mg are not one unit that can be converted without the named substance
- Package
- 100 tablets per bottle
- Labelled appearance
- yellow · round, unscored film-coated extended-release tablet, approximately 13 mm · imprint KC / 10Unscored; the cited label says to swallow it whole
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
KLOR-CON label reading: mEq is not mg, and an empty matrix is not a reason to repeat
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The 8 mEq (600 mg) and 10 mEq (750 mg) labels place the potassium electrolyte equivalent and potassium chloride mass on the same pack. The current KLOR-CON label says to swallow the tablet whole without crushing, chewing or sucking. Its wax matrix may be visible in stool; that does not prove failed absorption and is not a reason to repeat a tablet.
- mEq describes the electrolyte equivalent of a named ion, while mg describes the mass of a named substance. In this product, 8 mEq corresponds to 600 mg potassium chloride per tablet and 10 mEq to 750 mg, but that relationship must not be transferred to another ingredient, liquid concentration, injection or personal tablet count.
- This dossier covers an unscored wax-matrix KLOR-CON extended-release tablet whose label says to swallow whole. Do not crush, chew, suck or divide it to make a smaller amount. Similarly named KLOR-CON M is a different microencapsulated formulation, and its splitting or water-dispersion route must not be transferred to this product.
- Current labelling contraindicates co-use with triamterene or amiloride. ACE inhibitors, ARBs, spironolactone, eplerenone, aliskiren and NSAIDs may also increase hyperkalaemia risk. Do not stop a medicine yourself because both appear on a list; obtain prompt review of potassium, kidney function and the complete medicine list.
- Older adults more often have reduced kidney or cardiac function and multiple medicines, while hyperkalaemia may initially have no obvious symptoms. A pack or symptom cannot tell this site the potassium level, and bananas, supplements or potassium-containing salt substitutes do not replace laboratory and professional assessment.
- Severe vomiting, persistent or severe abdominal pain, marked distension, black stools or gastrointestinal bleeding need timely medical assessment. Severe chest symptoms, fainting, marked muscle weakness or a sense of abnormal rhythm warrants local emergency care. The site does not wait for these symptoms to resolve or infer a personal potassium amount from them.
- The unabsorbed wax matrix may be visible in stool. Like the empty-shell literacy of some other extended-release systems such as GLUCOTROL XL, a visible shell does not mean failed absorption, but the products must not be merged, substituted or repeated on that basis.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-29
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 3
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. KLOR-CON potassium chloride extended-release tablet NDA brand label (SPL v6; published 16 Jul 2025) ↗Current regulatory record · reviewed 2026-08-29
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- FDA · United States · Regulatory product record or label archive · 2026-08-29FDA Drugs@FDA: current KLOR-CON NDA 019123 application, RLD and RS records ↗reviewed 2026-08-29
- U.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-29DailyMed (NLM): current U.S. KLOR-CON M microencapsulated potassium chloride extended-release tablet label (used to distinguish formulations) ↗Current regulatory record · reviewed 2026-08-29
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about KLOR-CON (potassium chloride extended-release tablets). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
KLOR-CON is the brand in this record and potassium chloride extended-release tablets is the active-ingredient name. Check both with the dosage form (Potassium chloride wax-matrix film-coated extended-release oral tablets: 8 mEq (600 mg potassium chloride) or 10 mEq (750 mg potassium chloride) per tablet; swallow whole without crushing, chewing or sucking; not a KLOR-CON M microencapsulated extended-release tablet) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. KLOR-CON potassium chloride extended-release tablet NDA brand label (SPL v6; published 16 Jul 2025) ↗Current regulatory record · reviewed 2026-08-29
- FDA Drugs@FDA: current KLOR-CON NDA 019123 application, RLD and RS records ↗reviewed 2026-08-29
- DailyMed (NLM): current U.S. KLOR-CON M microencapsulated potassium chloride extended-release tablet label (used to distinguish formulations) ↗Current regulatory record · reviewed 2026-08-29
CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
When ALDACTONE / spironolactone is on the same list: review potassium, kidney function and the complete medicine list first
The current KLOR-CON label identifies spironolactone as a medicine that may increase hyperkalaemia risk. Bring both packs, all prescription and nonprescription medicines, supplements, potassium-containing salt substitutes and recent potassium and kidney-function results to a pharmacist or prescribing team. This card does not decide co-use or advise self-stopping, time-separation, replacement or adjustment of either medicine.
Open the Aldactone / spironolactone record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗Current regulatory record · reviewed 2026-08-29HOW IT WORKS · NOT A TREATMENT PLAN
How potassium chloride works: replenishing potassium does not mean automatically adding it to a diuretic
- Loop or thiazide diuretics may affect potassium, while potassium-sparing diuretics, ACE inhibitors, ARBs, ARNIs, spironolactone, NSAIDs, kidney-function changes and supplements may shift risk in another direction. ‘Taking a diuretic’ alone does not permit automatically adding KLOR-CON.
- 8 mEq/600 mg and 10 mEq/750 mg are two exact product strengths; mEq is not a tablet count. The site does not convert a laboratory value, body weight, diuretic amount or daily intake into a personal tablet count and provides no missed-use algorithm.
- Whole-genome screening is not a universal prerequisite set by this site for routine potassium supplementation. More directly relevant review usually includes the exact product, potassium trend, kidney function, ECG and clinical status, acid-base and other electrolytes, and the complete medicine list.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. KLOR-CON potassium chloride extended-release tablet NDA brand label (SPL v6; published 16 Jul 2025) ↗Current regulatory record · reviewed 2026-08-29
- FDA Drugs@FDA: current KLOR-CON NDA 019123 application, RLD and RS records ↗reviewed 2026-08-29
- FDA: KLOR-CON NDA 019123 original-review material (1986) ↗reviewed 2026-08-29
- DailyMed (NLM): current U.S. KLOR-CON M microencapsulated potassium chloride extended-release tablet label (used to distinguish formulations) ↗Current regulatory record · reviewed 2026-08-29
SOURCE-TRACEABLE ARCHIVE
KLOR-CONpotassium chloride extended-release tablets
This page includes an exact current U.S. public-label package panel for KLOR-CON, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
U.S. initial-approval year stated in the current label
This is a historical initial-approval field in the current label; alone it does not establish the approval date of the two exact NDA 019123 products, current supply or individual suitability.
DailyMed (NLM): current U.S. KLOR-CON potassium chloride extended-release tablet NDA brand label (SPL v6; published 16 Jul 2025) ↗FDA approved KLOR-CON 8/10 mEq under NDA 019123
FDA original-review material and the current Orange Book connect the wax-matrix extended-release 8/10 mEq products with this NDA.
FDA: KLOR-CON NDA 019123 original-review material (1986) ↗Current DailyMed SPL v6 published
The current record displays two exact 100-tablet bottle panels and the mEq/mg, intact-tablet, empty-matrix, kidney, gastrointestinal and co-medication boundaries.
DailyMed (NLM): current U.S. KLOR-CON potassium chloride extended-release tablet NDA brand label (SPL v6; published 16 Jul 2025) ↗
MARKET SCOPE
Market-record boundary
United States
Current prescription RLD extended-release tablets; 10 mEq is RSTwo 100-tablet bottle panels are recorded individually. Regulatory and package records do not establish real-time stock, purchasing eligibility, individual suitability or interchangeability with another potassium chloride formulation.
Mainland China, EU, Japan and other markets
Current market records not establishedNo local approval, dosage form, supply, originator/generic relationship or interchangeability is inferred from a U.S. brand name, shared ingredient, mEq/mg figures or pack colour.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Does 8 mEq (600 mg) mean the tablet contains 608 mg?
No. The 600 mg is the potassium chloride mass per tablet, while 8 mEq is the electrolyte equivalent of potassium supplied by it. They are two measurements describing one product strength, not numbers to add or transfer to another medicine.
The extended-release tablet is large. Can it be halved or dispersed in water?
This dossier covers an unscored wax-matrix KLOR-CON tablet whose current label says to swallow whole and not crush, chew or suck. Do not transfer different KLOR-CON M instructions. A swallowing difficulty requires review of the exact suitable formulation with a pharmacist or prescriber.
Can it be taken with spironolactone or an ARB?
The site cannot decide from names alone. Current labelling says RAAS inhibitors increase potassium-retention risk and require close monitoring; co-use with triamterene or amiloride is contraindicated. Do not stop or add a medicine yourself; professional review needs potassium, kidney function and the complete medicine list.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.